HUMA vs MDT vs BSX vs NVCR vs ZBH

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Humacyte, Inc. (HUMA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Boston Scientific Corporation at 29. 2x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: BSX returned +143. 6% versus HUMA's -89. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

30β versus Humacyte, Inc. 's 3. 33β — meaning HUMA is approximately 1010% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus -420. 2% for Humacyte, Inc. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -1197. 7% for HUMA. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zimmer Biomet Holdings, Inc.

(ZBH) trades at 9. 8x forward P/E versus 16. 7x for Boston Scientific Corporation — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HUMA: 177. 8% to $3. 00.

In this comparison, MDT (3.

6% yield), ZBH (1. 1% yield) pay a dividend. HUMA, BSX, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 6% yield). Humacyte, Inc. (HUMA) carries a higher beta of 3. 33 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, HUMA: -89. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HUMA is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; BSX is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; ZBH is a mid-cap quality compounder stock. MDT, ZBH pay a dividend while HUMA, BSX, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.